Bivalirudin
Products billed under this code include Bivalirudin.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Bivalirudin.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Bivalirudin | Sandoz Inc. | 00781-3158-95 | 2500 | $412.50 |
| Bivalirudin | Sandoz Inc. | 00781-9158-95 | 2500 | $412.50 |
| Bivalirudin | Accord Healthcare Inc | 16729-0275-67 | 2500 | $412.50 |
| Bivalirudin | Dr. Reddy's Laboratories Inc. | 55111-0652-37 | 2500 | $412.50 |
| Bivalirudin | Eugia US LLC | 55150-0210-10 | 2500 | $412.50 |
| Bivalirudin | FreseniUS Kabi USA, LLC | 63323-0562-10 | 2500 | $412.50 |
| Bivalirudin | FreseniUS Kabi USA, LLC | 63323-0562-15 | 2500 | $412.50 |
| Bivalirudin | Mylan Institutional LLC | 67457-0256-10 | 2500 | $412.50 |
| Bivalirudin | Slate Run Pharmaceuticals | 70436-0025-82 | 2500 | $412.50 |
| Bivalirudin | Meitheal Pharmaceuticals Inc. | 71288-0427-11 | 2500 | $412.50 |
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Bivalirudin | Meitheal Pharmaceuticals Inc. | 71288-0427-92 | 2500 | $412.50 |
| Bivalirudin | Civica, Inc. | 72572-0035-10 | 2500 | $412.50 |
| Bivalirudin | Avenacy Inc. | 83634-0400-10 | 2500 | $412.50 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $0.165 | −$0.001 | 1 MG | Bivalirudin | v1, posted September 17, 2026 |
| 3Q26 | $0.166 | +$0.042 | 1 MG | Bivalirudin | v1, posted September 15, 2026 |
| 2Q26 | $0.124 | −$0.033 | 1 MG | Bivalirudin | v1, posted September 15, 2026 |
| 1Q26 | $0.157 | −$0.012 | 1 MG | Bivalirudin | v1, posted September 15, 2026 |
| 4Q25 | $0.169 | +$0.003 | 1 MG | Bivalirudin | v1, posted September 8, 2026 |
| 3Q25 | $0.166 | +$0.013 | 1 MG | Bivalirudin | v1, posted March 10, 2026 |
| 2Q25 | $0.153 | −$0.01 | 1 MG | Bivalirudin | v1, posted March 10, 2026 |
| 1Q25 | $0.163 | −$0.004 | 1 MG | Bivalirudin | v1, posted December 19, 2025 |
| 4Q24 | $0.167 | −$0.035 | 1 MG | Bivalirudin | v1, posted June 11, 2025 |
| 3Q24 | $0.202 | −$0.044 | 1 MG | Bivalirudin | v1, posted June 11, 2025 |
| 2Q24 | $0.246 | +$0.032 | 1 MG | Bivalirudin | v1, posted March 11, 2025 |
| 1Q24 | $0.214 | +$0.028 | 1 MG | Bivalirudin | v1, posted December 19, 2024 |
| 4Q23 | $0.186 | −$0.052 | 1 MG | Bivalirudin | v1, posted October 10, 2024 |
| 3Q23 | $0.238 | +$0.051 | 1 MG | Bivalirudin | v1, posted June 5, 2024 |
| 2Q23 | $0.187 | −$0.074 | 1 MG | Bivalirudin | v1, posted February 23, 2024 |
| 1Q23 | $0.261 | −$0.148 | 1 MG | Bivalirudin | v1, posted December 6, 2023 |
| 4Q22 | $0.409 | +$0.122 | 1 MG | Bivalirudin | v1, posted June 22, 2023 |
| 3Q22 | $0.287 | −$0.075 | 1 MG | Bivalirudin | v1, posted June 9, 2023 |
| 2Q22 | $0.362 | −$0.057 | 1 MG | Bivalirudin | v1, posted December 14, 2022 |
| 1Q22 | $0.419 | +$0.129 | 1 MG | Bivalirudin | v1, posted June 8, 2022 |
| 4Q21 | $0.29 | −$0.048 | 1 MG | Bivalirudin | v1, posted June 2, 2022 |
| 3Q21 | $0.338 | −$0.259 | 1 MG | Bivalirudin | v1, posted June 2, 2022 |
| 2Q21 | $0.597 | +$0.15 | 1 MG | Bivalirudin | v1, posted March 1, 2022 |
| 1Q21 | $0.447 | – | 1 MG | Bivalirudin | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.